Insulin-like growth factor-I aerosol formulations for pulmonary delivery

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 85, Issue 1, 2013, Pages 61-68

  Germershaus, Oliver ^a   Schultz, Isabel ^a   Lühmann, Tessa ^a   Beck Broichsitter, Moritz ^b   Högger, Petra ^a   Meinel, Lorenz ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Aerosol; IGF I; IGF I aggregation; IGF I oxidation; Nebulization; Protein formulation

Indexed keywords

BUFFER; HISTIDINE; METHIONINE; SODIUM CHLORIDE; SOMATOMEDIN C; SUCCINIC ACID;

AEROSOL; ARTICLE; BIOASSAY; BIOLOGICAL ACTIVITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG OXIDATION; DRUG SCREENING; DRUG STABILITY; LIQUID; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEBULIZATION;

AEROSOL; IGF-I; IGF-I AGGREGATION; IGF-I OXIDATION; NEBULIZATION; PROTEIN FORMULATION;

ADMINISTRATION, INHALATION; AEROSOLS; BUFFERS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; EXCIPIENTS; GROWTH SUBSTANCES; HUMANS; HYDROGEN-ION CONCENTRATION; INSULIN-LIKE GROWTH FACTOR I; NEBULIZERS AND VAPORIZERS; OXIDATION-REDUCTION; PARTICLE SIZE; PROTEIN STABILITY; RECOMBINANT PROTEINS; RESPIRATORY SYSTEM AGENTS; SALINITY; SOLUBILITY;

EID: 84882974134     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.03.011     Document Type: Article

References (47)

1. A. Juul Serum levels of insulin-like growth factor I and its binding proteins in health and disease Growth Horm. IGF Res. 13 2003 113 170
2. M. Pollak Insulin-like growth factor physiology and cancer risk Eur. J. Cancer 36 2000 1224 1228
3. J. Zapf, and E.R. Froesch Insulin-like growth factors/somatomedins: structure, secretion, biological actions and physiological role Horm. Res. 24 1986 121 130
4. Scientific Discussion Increlex EPAR 2007 European Medicines Agency London
5. L. Meinel, O.E. Illi, J. Zapf, M. Malfanti, H.P. Merkle, and B. Gander Stabilizing insulin-like growth factor-I in poly(d,l-lactide-co-glycolide) microspheres J. Control. Release 70 2001 193 202
6. M. Singh, B. Shirley, K. Bajwa, E. Samara, M. Hora, and D. O'Hagan Controlled release of recombinant insulin-like growth factor from a novel formulation of polylactide-co-glycolide microparticles J. Control. Release 70 2001 21 28
7. X.M. Lam, E.T. Duenas, A.L. Daugherty, N. Levin, and J.L. Cleland Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes J. Control. Release 67 2000 281 292
8. S.R. Mao, J. Xu, C.F. Cai, O. Germershaus, A. Schaper, and T. Kissel Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres Int. J. Pharm. 334 2007 137 148
9. M.L. Houchin, and E.M. Topp Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms J. Pharm. Sci. 97 2008 2395 2404
10. Y. Zhang, and S.P. Schwendeman Minimizing acylation of peptides in PLGA microspheres J. Control. Release 162 2012 119 126
11. T. Estey, J. Kang, S.P. Schwendeman, and J.F. Carpenter BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems J. Pharm. Sci. 95 2006 1626 1639
12. M. Gansslen Uber die inhalation von insulin Klin. Wochenschrift 4 1925 71
13. W. Heubner, S.E. De Jongh, and E. Laquer Uber die inhalation von insulin Klin. Wochenschrift 3 1924 2342
14. S. White, D.B. Bennett, S. Cheu, P.W. Conley, D.B. Guzek, S. Gray, J. Howard, R. Malcolmson, J.M. Parker, P. Roberts, N. Sadrzadeh, J.D. Schumacher, S. Seshadri, G.W. Sluggett, C.L. Stevenson, and N.J. Harper EXUBERA: pharmaceutical development of a novel product for pulmonary delivery of insulin Diabetes Technol. Ther. 7 2005 896 906
15. T. Quattrin, A. Belanger, N.J. Bohannon, and S.L. Schwartz Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial Diabetes Care 27 2004 2622 2627
16. P.A. Hollander, L. Blonde, R. Rowe, A.E. Mehta, J.L. Milburn, K.S. Hershon, J.L. Chiasson, and S.R. Levin Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial Diabetes Care 27 2004 2356 2362
17. D.R. Clemmons Insulin like growth factors - their binding proteins and growth regulation E. Canalis, Skeletal Growth Factors 2000 Lippincott Williams & Wilkins Philadelphia 79 99
18. E. Rinderknecht, and R.E. Humbel The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin J. Biol. Chem. 253 1978 2769 2776
19. P. Royle, N. Waugh, L. McAuley, L. McIntyre, and S. Thomas Inhaled insulin in diabetes mellitus Cochrane Database Syst. Rev. 2004 CD003890
20. J.R. Fransson Oxidation of human insulin-like growth factor I in formulation studies. 3. Factorial experiments of the effects of ferric ions, EDTA, and visible light on methionine oxidation and covalent aggregation in aqueous solution J. Pharm. Sci. 86 1997 1046 1050
21. J. Fransson, E. Florin-Robertsson, K. Axelsson, and C. Nyhlen Oxidation of human insulin-like growth factor I in formulation studies: kinetics of methionine oxidation in aqueous solution and in solid state Pharmaceut. Res. 13 1996 1252 1257
22. J. Fransson, and A. Hagman Oxidation of human Insulin-like Growth Factor I in formulation studies. 2. Effects of oxygen, visible light, and phosphate on methionine oxidation in aqueous solution and evaluation of possible mechanisms Pharmaceut. Res. 13 1996 1476 1481
23. J. Fransson, D. Hallen, and E. Florin-Robertsson Solvent effects on the solubility and physical stability of human Insulin-like Growth Factor I Pharmaceut. Res. 14 1997 606 612
24. Guideline Q1A: Stability testing of new drug substances and products, in: I.C.o. Harmonization (Ed.) Q1A(R2), 2003.
25. E. Wenk, A.J. Meinel, S. Wildy, H.P. Merkle, and L. Meinel Microporous silk fibroin scaffolds embedding PLGA microparticles for controlled growth factor delivery in tissue engineering Biomaterials 30 2009 2571 2581
26. M. Beck-Broichsitter, P. Kleimann, T. Schmehl, T. Betz, U. Bakowsky, T. Kissel, and W. Seeger Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers Eur. J. Pharm. Biopharm. 82 2012 272 280
27. H. Steckel, F. Eskandar, and K. Witthohn Effect of excipients on the stability and aerosol performance of nebulized aviscumine J. Aerosol Med.: Off. J. Int. Soc. Aerosol Med. 16 2003 417 432
28. N.V. Katre, J. Asherman, H. Schaefer, and M. Hora Multivesicular liposome (DepoFoam) technology for the sustained delivery of insulin-like growth factor-I (IGF-I) J. Pharm. Sci. 87 1998 1341 1346
29. M.C. Manning, D.K. Chou, B.M. Murphy, R.W. Payne, and D.S. Katayama Stability of protein pharmaceuticals: an update Pharmaceut. Res. 27 2010 544 575
30. E.Y. Chi, S. Krishnan, T.W. Randolph, and J.F. Carpenter Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation Pharmaceut. Res. 20 2003 1325 1336
31. B.S. Kendrick, T. Li, and B.S. Chang Physical stabilization of proteins in aqueous solution J.F. Carpenter, M.C. Manning, Rationale Design of Stable Protein Formulations - Theory and Practice 2002 Kluwer Academics/Plenum publishers New York 61 84
32. T.H. Nguyen, Oxidation degradation of protein pharmaceuticals, in: J.L. Cleland, R. Langer (Eds.) Formulation and Delivery of Proteins and Peptides, ACS Symposium Series, Washington, DC, 1994.
33. J. Yin, J.W. Chu, M.S. Ricci, D.N. Brems, D.I. Wang, and B.L. Trout Effects of antioxidants on the hydrogen peroxide-mediated oxidation of methionine residues in granulocyte colony-stimulating factor and human parathyroid hormone fragment 13-34 Pharmaceut. Res. 21 2004 2377 2383
34. X.M. Lam, J.Y. Yang, and J.L. Cleland Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2 J. Pharm. Sci. 86 1997 1250 1255
35. E. Canova-Davis, M. Eng, V. Mukku, D.H. Reifsnyder, C.V. Olson, and V.T. Ling Chemical heterogeneity as a result of hydroxylamine cleavage of a fusion protein of human insulin-like growth factor I Biochem. J. 285 Pt 1 1992 207 213
36. G. Forsberg, G. Palm, A. Ekebacke, S. Josephson, and M. Hartmanis Separation and characterization of modified variants of recombinant human insulin-like growth factor I derived from a fusion protein secreted from Escherichia coli Biochem. J. 271 1990 357 363
37. H.J. Lee, A. McAuley, K.F. Schilke, and J. McGuire Molecular origins of surfactant-mediated stabilization of protein drugs Adv. Drug Deliver. Rev. 63 2011 1160 1171
38. H. Steckel, and F. Eskandar Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers Eur. J. Pharm. Sci. 19 2003 443 455
39. Y. Wu, J. Levons, A.S. Narang, K. Raghavan, and V.M. Rao Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility AAPS PharmSciTech 12 2011 1248 1263
40. S. Li, C. Schoneich, and R.T. Borchardt Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization Biotechnol. Bioeng. 48 1995 490 500
41. L.C. Konigsberger, E. Konigsberger, P.M. May, and G.T. Hefter Complexation of iron(III) and iron(II) by citrate. Implications for iron speciation in blood plasma J. Inorg. Biochem. 78 2000 175 184
42. A.M. Wade, and H.N. Tucker Antioxidant characteristics of l-histidine J. Nutr. Biochem. 9 1998 308 315
43. H.C. Mahler, W. Friess, U. Grauschopf, and S. Kiese Protein aggregation: pathways, induction factors and analysis J. Pharm. Sci. 98 2009 2909 2934
44. S. Majumdar, B.M. Ford, K.D. Mar, V.J. Sullivan, R.G. Ulrich, and A.J. D'Souza Evaluation of the effect of syringe surfaces on protein formulations J. Pharm. Sci. 100 2011 2563 2573
45. S.A. Shoyele, and A. Slowey Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery Int. J. Pharm. 314 2006 1 8
46. R.W. Niven, S.J. Prestrelski, M.J. Treuheit, A.Y. Ip, and T. Arakawa Protein nebulization. 2. Stabilization of G-CSF to air-jet nebulization and the role of protectants Int. J. Pharm. 127 1996 191 201
47. H. Steckel, F. Eskandar, and K. Witthohn The effect of formulation variables on the stability of nebulized aviscumine Int. J. Pharm. 257 2003 181 194